tirzepatide cardiovascular outcomes trial results july 2025 in Diabetes: New Evidence From Trials SURPASS-CVOT Published: Large Trial Confirms

With an increasing number of similar GLP-1 drugs now being used in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our findings highlight the potential for these existing drugs to be repurposed to treat the risk of no-reflow in heart attack patients, offering a potentially life-saving solution, said University College London Professor David Atwell

Insulin helps muscle and fat cells absorb glucose for energy

Clinical trial data from the SURMOUNT-5 trial shows tirzepatide produced approximately 47 percent more weight loss than a semaglutide comparator over 72 weeks (average of 50 pounds versus 33 pounds)

Morgantown, WV: Mylan Pharmaceuticals

Three or four temperature cycles between room temperature and refrigerator cause cumulative damage that compounds with each cycle